Endo’s Response to COVID-19

For decades, people have trusted Endo to provide medicines which help them lead healthier lives.

As the global coronavirus (COVID-19) pandemic continues to evolve, our role in providing safe, high-quality products to the patients and providers who rely on us is more important than ever.

Guided by our commitment to the safety of our team members and the communities where we live and work, as well as a commitment to continue to reliably supply the critical medicines needed by healthcare providers and the patients they care for, Endo has implemented a comprehensive response to COVID-19.

Health and Safety of Our Employees

We have taken, and will continue to take, proactive measures to ensure the well-being of our team members around the globe while continuing to safely produce products upon which patients and their healthcare providers rely. In March, we implemented work from home requirements for team members who are able to do so. For those who continued to come to work, we reduced operating staff, increased social distancing and enhanced our already rigorous sanitization efforts throughout all of our facilities. Guided by local and national health authority guidelines, we are beginning to bring team members back to our locations. We will continuously reassess policies in accordance with health authorities and in support of our employees, communities and customers.

Commitment to Our Patients

Endo’s global manufacturing sites and related distribution channels are operational and have not experienced significant supply disruptions.  As part of our commitment to meet the demand for critical care and medically necessary products, we have prioritized those operations. In addition, we implemented enhanced safety measures at each of our manufacturing facilities including modified work schedules so that fewer colleagues are present at once, increased social distancing and restricted site access to only essential workers.

Patients who have questions or concerns about their medications or treatment plan should consult with their healthcare provider. For additional questions or concerns, please contact the Endo Customer Service team at (800) 462-ENDO-(3636), the Par Customer Service team at (800) 828-9393 or Paladin Customer Service team at (866) 340-1112.

Clinical Trials and R&D Efforts

We have a number of ongoing clinical trials, and we are committed to the safety of the patients and Endo team members involved. We currently anticipate only modest delays in patient recruitment and site selection for new clinical trials as a result of the impact of COVID-19.

Last Updated: June 5, 2020.

For a French translation of this page, click here.